Beta Knife treatment describes the utilization of beta emitting radionuclides for neoplastic cancer or non neoplastic benign conditions; The treatments could be administered orally, intravenously, intraarterially, intralymphatically, or intratumorally; The carrier agent/drug linked to the beta emitting radionuclide could be in a simple chemical form or could be a peptide, an antibody, a complex particle, a microsphere or any active biochemical constituent ; A more detailed list of product and treatment designations that the "Beta Knife" trademark is applicable is as follows Radioactive Iodine Therapy or radioiodine therapy for thyroid cancer Radiopeptide Therapy or radioreceptor therapy for carcinoid, neuroendocrine tumors, and all other solid tumor treatments administered by means of a beta emitting radioisotope associated with a tumor-specific peptide Radioimmuno Therapy for solid tumors; All treatments administered by means of a beta emitting radioisotope associated with a tumor-specific monoclonal antibody ; Radiomicrosphere Therapy or selective internal radiation treatment, or liver directed brachytherapy, or radioembolization for primary and metastatic liver cancer